BioCryst Pharmaceuticals, Inc. (BCRX): Price and Financial Metrics

BioCryst Pharmaceuticals, Inc. (BCRX): $8.80

0.23 (+2.68%)

POWR Rating

Component Grades













Add BCRX to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where BCRX ranks best; there it ranks ahead of 67.99% of US stocks.
  • BCRX's strongest trending metric is Stability; it's been moving down over the last 179 days.
  • BCRX's current lowest rank is in the Stability metric (where it is better than 1.92% of US stocks).

BCRX Stock Summary

  • Biocryst Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 3.78% of US listed stocks.
  • BCRX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 3.19% of US stocks.
  • As for revenue growth, note that BCRX's revenue has grown 782.38% over the past 12 months; that beats the revenue growth of 98.72% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Biocryst Pharmaceuticals Inc are CYTK, VERU, LOGC, EXEL, and DNN.
  • Visit BCRX's SEC page to see the company's official filings. To visit the company's web site, go to

BCRX Valuation Summary

  • In comparison to the median Healthcare stock, BCRX's EV/EBIT ratio is 155.97% lower, now standing at -16.4.
  • Over the past 243 months, BCRX's EV/EBIT ratio has gone down 11.7.
  • BCRX's EV/EBIT ratio has moved down 11.7 over the prior 243 months.

Below are key valuation metrics over time for BCRX.

Stock Date P/S P/B P/E EV/EBIT
BCRX 2021-08-31 36.0 -26.8 -13.3 -16.4
BCRX 2021-08-30 35.5 -26.5 -13.1 -16.1
BCRX 2021-08-27 35.4 -26.4 -13.1 -16.1
BCRX 2021-08-26 34.7 -25.9 -12.8 -15.8
BCRX 2021-08-25 35.0 -26.1 -12.9 -15.9
BCRX 2021-08-24 34.9 -26.1 -12.9 -15.9

BCRX Growth Metrics

    The 2 year net income to common stockholders growth rate now stands at -49.27%.
  • The 5 year net income to common stockholders growth rate now stands at -127.75%.
  • Its 2 year revenue growth rate is now at 142.19%.
Over the past 52 months, BCRX's revenue has gone up $126,891,000.

The table below shows BCRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 157.17 -142.157 -184.062
2021-09-30 114.028 -154.337 -226.776
2021-06-30 79.136 -169.316 -214.09
2021-03-31 32.048 -174.946 -209.499
2020-12-31 17.812 -137.216 -182.814
2020-09-30 53.521 -103.025 -124.943

BCRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BCRX has a Quality Grade of C, ranking ahead of 64.73% of graded US stocks.
  • BCRX's asset turnover comes in at 0.295 -- ranking 153rd of 682 Pharmaceutical Products stocks.
  • BLCM, VIRX, and GLYC are the stocks whose asset turnover ratios are most correlated with BCRX.

The table below shows BCRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.295 0.901 -0.933
2021-03-31 0.127 0.766 -1.361
2020-12-31 0.083 0.906 -2.051
2020-09-30 0.305 0.922 -3.095
2020-06-30 0.319 0.946 -2.677
2020-03-31 0.368 0.944 -1.858

BCRX Price Target

For more insight on analysts targets of BCRX, see our BCRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $21.27 Average Broker Recommendation 1.58 (Moderate Buy)

BCRX Stock Price Chart Interactive Chart >

Price chart for BCRX

BCRX Price/Volume Stats

Current price $8.80 52-week high $19.99
Prev. close $8.57 52-week low $7.61
Day low $8.45 Volume 2,199,142
Day high $8.83 Avg. volume 4,736,477
50-day MA $11.90 Dividend yield N/A
200-day MA $13.96 Market Cap 1.63B

BioCryst Pharmaceuticals, Inc. (BCRX) Company Bio

Biocryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. The company was founded in 1986 and is based in Durham, North Carolina.

BCRX Latest News Stream

Event/Time News Detail
Loading, please wait...

BCRX Latest Social Stream

Loading social stream, please wait...

View Full BCRX Social Stream

Latest BCRX News From Around the Web

Below are the latest news stories about Biocryst Pharmaceuticals Inc that investors may wish to consider to help them evaluate BCRX as an investment opportunity.

BioCryst posts long-term data for hereditary angioedema therapy

On Thursday, BioCryst Pharmaceuticals (NASDAQ:BCRX) highlighted the long-term potential of its oral hereditary angioedema (HAE) therapy Orladeyo after the release of the latest data from its APeX-2 trial designed to evaluate the once-daily drug as a prophylactic treatment. 96-week data of the 121-patient trial were previously disclosed in July 2021,...

Seeking Alpha | February 24, 2022

BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among HAE Patients Following Long-Term Treatment with ORLADEYO® (berotralstat)

— Analysis from APeX-2 showed 94 percent attack-free days across all patients who completed 96 weeks of treatment —RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new long-term efficacy and safety data from the APeX-2 clinical trial evaluating oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) showing sustained reductions in attack rates and improvement in quality of

Yahoo | February 24, 2022

BioCryst Pharmaceuticals Non-GAAP EPS of -$0.40 misses by $0.11, revenue of $47.2M misses by $3.28M

BioCryst Pharmaceuticals press release (NASDAQ:BCRX): Q4 Non-GAAP EPS of -$0.40 misses by $0.11. Revenue of $47.2M (+1080.0% Y/Y) misses by $3.28M. ORLADEYO net revenue in the fourth quarter of 2021 was $46.2M. Cash, cash equivalents, restricted cash and investments totaled $517.8 million as of December 31, 2021, compared to $302.6...

Seeking Alpha | February 23, 2022

Recap: BioCryst Pharmaceuticals Q4 Earnings

BioCryst Pharmaceuticals (NASDAQ: BCRX ) reported its Q4 earnings results on Wednesday, February 23, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings BioCryst Pharmaceuticals missed estimated earnings by 33.33%, reporting an EPS of $-0.4 versus Full story available on

Benzinga | February 23, 2022

BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 23, 2022

Read More 'BCRX' Stories Here

BCRX Price Returns

1-mo -12.61%
3-mo -47.24%
6-mo -29.49%
1-year -33.73%
3-year 165.06%
5-year 52.51%
YTD -36.46%
2021 85.91%
2020 115.94%
2019 -57.25%
2018 64.36%
2017 -22.43%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6505 seconds.